Earnings per share for the last twelve months: Checkpoint Therapeutics Inc. (CKPT)
The cancer treatment sector serves as a defensive asset independent of global crises. The trailing twelve-month earnings per share on the GURU.Markets chart clearly confirms this trend, where the -1.14 indicator determines the metric's magnitude. The stability of Checkpoint Therapeutics (CKPT) is supported by production outsourcing in the US and Europe, although geopolitical tensions and sanctions periodically complicate biomaterial logistics and clinical trials.
Analytical breakdowns for Checkpoint Therapeutics Inc. (CKPT)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Checkpoint Therapeutics, Inc|CKPT - Company Cumulative Debt|Debts to Book Capitalization Checkpoint Therapeutics, Inc.|CKPT - Company Long-Term Liabilities|Company Short-Term Debt Checkpoint Therapeutics|Quick Liquidity checkpointtx.com
- net income and valuation multiples indicators:
CKPT - Profit After Tax|Expected Profit Checkpoint Therapeutics|CKPT - Market Cap to Earnings|Forward P/E Multiple Checkpoint Therapeutics, Inc.|CKPT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc.|CKPT - Operating profit before amortization|Net earnings per share for the last 12 months Checkpoint Therapeutics|CKPT - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months checkpointtx.com|CKPT - Earnings per share increase in current year|Expected earnings per share growth for next year Checkpoint Therapeutics
Basic company analysis:Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics is integrating ESG standards into biopharmaceuticals by reducing chemical waste during the development of immuno-oncology agents. This metric measures the total earnings per common share over the last 12 months. Investors assess management efficiency based on the ability to transform demand into actual profit. An increase in this value confirms the market resilience of the business. Analyzing the company's annual net income per share allows for the timely detection of rising cost risks.
Competitor analysis
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share (EPS TTM) BCAX|Net earnings per share for the last 12 months personalis.com PSNL|Net earnings per share (EPS TTM) ERAS (Erasca)|Earnings per share for the trailing year DCTH|YmAbs - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aura Corp|CADL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months accuray.com|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Net earnings per share (EPS TTM) Actuate Therapeutics Inc.|Earnings per share for the last twelve months Citius Oncology, Inc (CTOR)|HURA: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Protara Therapeutics TARA|fatetherapeutics.com (FATE) - Net earnings per one share for the last twelve months|Aadi Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters TScan Therapeutics TCRX|championsoncology.com (CSBR) - Earnings per share for the last twelve months|Earnings per share for the last 12 months XBIT|Net earnings per share for the last 12 months CVM|OSTX (ostherapies.com) - Earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|ARTV (artivabio.com) - Earnings per share for the trailing year|Adlai Nortye - Net earnings per share for the last 12 months|Earnings per share for the last four quarters VERU (Veru Corporation)|Tempest Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year XLO (Xilio Therapeutics, Inc.)|RENB: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Mural Oncology (MURA)|Earnings per share for the last twelve months Kairos Pharma Limited|OKUR: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GDTC|Net earnings per share (EPS TTM) curis.com (CRIS)|Earnings per share for the last twelve months Apollomics APLM|THAR (Tharimmune Inc) - Earnings per one share for the last 12 months|Advanced Biomed Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Genprex Inc|CLDI (calidibio.com) - Net earnings per share for the last 12 months|Sunshine Biopharma Inc. (SBFM) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months XBIO|SLRX (Salarius Pharmaceuticals Inc) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) PPBT|Net earnings per share for the last four quarters aoncology.com|Net earnings per share (EPS TTM) BGNE (BeiGene, Ltd.)|ELEV - Net earnings per share for the last 12 months|ICAD - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Ikena Oncology, Inc. IKNA|NTBL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Viracta Therapeutics, Inc.|Earnings per share for the last twelve months MorphoSys AG|Net earnings per share (EPS TTM) nayabiosciences.com|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
